Perampanel
پرامپانل
🧠 Nervous SystemAMPA receptor antagonist (antiepileptic)
Market / country: 🇺🇸 USA
Fycompa (US)
🧮 Dose calculator
Epilepsy (complex partial / absence seizures) · Regimen source: FDA Fycompa · 2.1
- • With moderate/strong CYP3A4 inducers (carbamazepine, phenytoin, oxcarbazepine) start at 4 mg. Primary generalised tonic-clonic (≥12 y): maintenance 8 mg. FDA Fycompa · 2FDA Fycompa · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Warnings
- • Boxed warning: serious psychiatric and behavioural reactions (aggression, hostility, homicidal ideation). FDA Fycompa · Boxed Warning
Formulations
- 2 mg tablet — tablet 🇺🇸 USA FDA Fycompa · 3
- 4 mg tablet — tablet 🇺🇸 USA FDA Fycompa · 3
- 6 mg tablet — tablet 🇺🇸 USA FDA Fycompa · 3
- 8 mg tablet — tablet 🇺🇸 USA FDA Fycompa · 3
- 10 mg tablet — tablet 🇺🇸 USA FDA Fycompa · 3
- 12 mg tablet — tablet 🇺🇸 USA FDA Fycompa · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Fycompa · 8.1
“Risk Summary There are no adequate data on the developmental risk associated with use in pregnant women.”
- 🤱 BreastfeedingNo data
The source for this drug has no section for this group.
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Fycompa · 8.4
“Safety and effectiveness of FYCOMPA for the treatment of partial-onset seizures have been established in pediatric patients 4 years of age and older.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Fycompa · 8.5
“Clinical studies of FYCOMPA did not include sufficient numbers of patients aged 65 and over to determine the safety and efficacy of FYCOMPA in the elderly population.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Fycompa · 8.3
“Contraception Use of FYCOMPA may reduce the efficacy of hormonal contraceptives containing levonorgestrel.”
🔗 Reference links
- FDA (approval record)NDA202834
- DailyMed (FDA label)FDA Fycompa
- MedlinePlus (NIH)Perampanel
- WHO ATC/DDDN03AX22
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Fycompa · 3FDA Fycompa · 2.1FDA Fycompa · 2FDA Fycompa · 2.2FDA Fycompa · Boxed WarningFDA Fycompa · SPL approval / marketing categoryFDA Fycompa · 8.1FDA Fycompa · 8.4FDA Fycompa · 8.5FDA Fycompa · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified